PAPER Rapp T, Andrieu S, Molinier L, Grand A, Cantet C, Mullins CD, Vellas B
SEARCH RESULTS
269790 RESULTS
PAPER Chen TS, Lang HC
Cost-effectiveness analysis of donepezil and rivastigmine for mild to moderate Alzheimer's disease in Taiwan.
Value Health. 2013 May;16(3):A104. PubMed.PAPER Wang L, Zhang J, Li L, Baser O
Clinical and economic burden of veteran alzheimer's disease patients in the United States: A real-world evaluation.
Value Health. 2013 May;16(3):A101. PubMed.PAPER Lacey L, Bobula J, Rüdell K, Alvir J, Leibman C
Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
Value Health. 2015 Jul;18(5):638-45. Epub 2015 Apr 10 PubMed.PAPER Rapp T, Lacey L, Ousset PJ, Cowppli-Bony P, Vellas B, Orgogozo JM
An Analysis of the Public Financial Support Eligibility Rule for French Dependent Elders with Alzheimer's Disease.
Value Health. 2015 Jul;18(5):553-9. Epub 2015 Jun 5 PubMed.PAPER Belger M, Argimon JM, Dodel R, Haro JM, Wimo A, Reed C
Comparing Resource Use In Alzheimer's Disease Across Three European Countries- 18-Month Results of The Geras Study.
Value Health. 2015 Nov;18(7):A759-60. Epub 2015 Oct 20 PubMed.PAPER Coste F, Neumann PJ, Xie L, Sanon M, Bent-Ennakhil N, Wang Y, Kariburyo MF, Fillit H
An Update on Healthcare Resource Use and Economic Burden In Alzheimer's Disease In The United States (Us) From A Medicare Sample Analysis.
Value Health. 2015 Nov;18(7):A754. Epub 2015 Oct 20 PubMed.PAPER Dokuyucu O, Saylan M, Ozdemir O, Keskinaslan A
Inequity in Access to Alzheimer Disease Indicated Treatment Across Different Geographic Areas of Turkey.
Value Health. 2015 Nov;18(7):A413-4. Epub 2015 Oct 20 PubMed.PAPER Hanna ML, Pickering MK, Albrecht J, Oehrlein EM, Patterson CR, Musallam AJ, Perfetto EM
Twenty-Year Trends In Diagnosis and Treatment of Alzheimer's Disease.
Value Health. 2015 Nov;18(7):A749. Epub 2015 Oct 20 PubMed.PAPER Hong Y, Pickering MK, Perfetto EM, Albrecht J, Ung B, Yang K, Lederer H
"Big Data" In Alzheimer's Disease Research: An Environmental Scan.
Value Health. 2015 Nov;18(7):A691. Epub 2015 Oct 20 PubMed.PAPER Kruntoradova K, Mandelikova M, Mlcoch T, Dolezal T
Cost-Effectiveness Analysis of Ginkgo Biloba Extract (Egb761®- Tanakan®) for The Treatment of Dementia In The Czech Republic.
Value Health. 2015 Nov;18(7):A756. Epub 2015 Oct 20 PubMed.PAPER Martin A
Humanistic Burden in Dementia: Which Tools Were Most Commonly Used in Studies Published in Pubmed in 2014?
Value Health. 2015 Nov;18(7):A412-3. Epub 2015 Oct 20 PubMed.PAPER Mohana Devi S, Sasikala K, Balachandar V
A Study On Cytogenetic And Molecular Analysis Of Presenilin 1 (Ps1) Gene In Alzheimer's Disease.
Value Health. 2015 Nov;18(7):A683. Epub 2015 Oct 20 PubMed.PAPER Rapp T, Vellas B, Andrieu S, Chartier F, Baraille L, Belger M
Observational Study of Resource use and Cost of Alzheimer's Disease in Europe (Geras)- 18-Month Results from the French Cohort.
Value Health. 2015 Nov;18(7):A409. Epub 2015 Oct 20 PubMed.PAPER Roth JA, Cohen JT, Veenstra DL, Chen E, Jhuti GS, Neumann PJ, Sullivan SD
Development of A Cost-Effectiveness Analysis Framework for Modeling Treatment of Alzheimer's Disease And Mild Cognitive Impairment.
Value Health. 2015 Nov;18(7):A698-9. Epub 2015 Oct 20 PubMed.Current Filters
- TYPE: Paper x